In today’s briefing:
- Meta Health: Forging a Digital Future for Healthcare
- Giant Biogene IPO: Strong Growth Prospects Offsets Short-Term Margin Concerns
- Seegene (096530 KS): Recovery of Non-COVID Sales to Drive Future Growth
Meta Health: Forging a Digital Future for Healthcare
- Meta Health: Forging a Digital Future for Healthcare As a result, my leadership style is one of servant leadership,” said the Chairman and Chief Executive Officer of SGX-listed Meta Health Ltd.
- With more than two decades of professional experience in the pharmaceutical and consumer health industries, Ng is well-positioned to oversee Meta Health’s pivot to the digital healthcare space.
Giant Biogene IPO: Strong Growth Prospects Offsets Short-Term Margin Concerns
- Giant Biogene Holding (GBH HK) designs, develops and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient in China.
- The company has filed for an IPO on the Hong Kong Stock Exchange and plans to raise proceeds of around HK$500m.
- We remain positive on Biogene’s growth prospects as it operates in a growing market which should further benefit from regulatory tailwinds.
Seegene (096530 KS): Recovery of Non-COVID Sales to Drive Future Growth
- Seegene Inc (096530 KS) reported a 30% y/y growth in revenue from non-COVID products to KRW69.5 billion in H1 2022. Q2 non-COVID product revenue was up 21% compared to Q1.
- The company expects strong demand for respiratory virus testing in fall and winter as the flu season starts in its key markets of Europe and North America.
- Seegene stock is trading near its lows, mainly due to muted financial performance. Seegene can be a value pick and long-term play on the non-COVID product recovery.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars